James Marsh
Concepts (523)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Myocardium | 47 | 2008 | 429 | 2.580 |
Why?
| Calcium Channels, L-Type | 17 | 2008 | 67 | 1.930 |
Why?
| Myocardial Contraction | 36 | 2010 | 105 | 1.510 |
Why?
| Calcium Channels | 13 | 2006 | 46 | 1.040 |
Why?
| Calcium | 33 | 2017 | 397 | 1.030 |
Why?
| Platelet Aggregation Inhibitors | 4 | 2017 | 174 | 0.970 |
Why?
| Stroke | 3 | 2019 | 492 | 0.930 |
Why?
| Genetic Therapy | 3 | 2009 | 114 | 0.890 |
Why?
| Platelet Function Tests | 2 | 2013 | 17 | 0.860 |
Why?
| Blood Platelets | 3 | 2017 | 245 | 0.830 |
Why?
| Purinergic P2Y Receptor Antagonists | 2 | 2013 | 29 | 0.820 |
Why?
| Rats | 37 | 2010 | 3300 | 0.780 |
Why?
| Ion Channels | 9 | 2009 | 72 | 0.770 |
Why?
| Myocytes, Cardiac | 8 | 2010 | 125 | 0.720 |
Why?
| Coronary Disease | 6 | 2004 | 132 | 0.720 |
Why?
| Brain Ischemia | 2 | 2019 | 161 | 0.690 |
Why?
| Fluorocarbons | 1 | 2019 | 45 | 0.670 |
Why?
| Heart | 16 | 2002 | 326 | 0.660 |
Why?
| Biomedical Research | 3 | 2018 | 231 | 0.650 |
Why?
| Neuroprotective Agents | 1 | 2019 | 105 | 0.630 |
Why?
| Animals | 70 | 2012 | 13150 | 0.620 |
Why?
| Research Personnel | 2 | 2018 | 62 | 0.620 |
Why?
| Cells, Cultured | 39 | 2008 | 1571 | 0.620 |
Why?
| Muscle, Smooth, Vascular | 5 | 2006 | 131 | 0.610 |
Why?
| Receptors, Adrenergic, beta | 11 | 2000 | 42 | 0.610 |
Why?
| Personnel Selection | 1 | 2017 | 24 | 0.600 |
Why?
| Internal Medicine | 1 | 2017 | 19 | 0.600 |
Why?
| Heart Ventricles | 21 | 2010 | 248 | 0.590 |
Why?
| Cardiovascular Diseases | 4 | 2020 | 440 | 0.580 |
Why?
| Leadership | 1 | 2017 | 100 | 0.570 |
Why?
| Faculty, Medical | 1 | 2017 | 90 | 0.560 |
Why?
| Calcium Channel Blockers | 8 | 2000 | 62 | 0.520 |
Why?
| Isoproterenol | 14 | 2002 | 57 | 0.500 |
Why?
| Physician's Role | 1 | 2014 | 48 | 0.480 |
Why?
| Sodium-Calcium Exchanger | 6 | 2004 | 8 | 0.470 |
Why?
| RNA, Messenger | 17 | 2005 | 1105 | 0.460 |
Why?
| Education, Medical | 1 | 2014 | 112 | 0.440 |
Why?
| Chest Pain | 1 | 2013 | 53 | 0.440 |
Why?
| Rats, Sprague-Dawley | 20 | 2005 | 1595 | 0.430 |
Why?
| Ticlopidine | 1 | 2013 | 55 | 0.430 |
Why?
| Coronary Artery Disease | 3 | 2012 | 274 | 0.410 |
Why?
| Angioplasty, Balloon, Coronary | 2 | 2012 | 130 | 0.400 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2010 | 138 | 0.380 |
Why?
| Acute Coronary Syndrome | 1 | 2012 | 78 | 0.370 |
Why?
| Transcription, Genetic | 6 | 2002 | 371 | 0.370 |
Why?
| Excitation Contraction Coupling | 1 | 2010 | 2 | 0.370 |
Why?
| Calcium Signaling | 1 | 2010 | 56 | 0.360 |
Why?
| Cardiomegaly | 3 | 1998 | 34 | 0.350 |
Why?
| Chick Embryo | 24 | 1993 | 83 | 0.340 |
Why?
| Promoter Regions, Genetic | 2 | 2002 | 477 | 0.330 |
Why?
| Emergency Service, Hospital | 1 | 2013 | 488 | 0.330 |
Why?
| Hypertension | 5 | 2020 | 532 | 0.330 |
Why?
| Protein Subunits | 4 | 2008 | 77 | 0.320 |
Why?
| Norepinephrine | 4 | 2002 | 107 | 0.310 |
Why?
| Molecular Mimicry | 1 | 2008 | 38 | 0.310 |
Why?
| Humans | 35 | 2020 | 49827 | 0.300 |
Why?
| Troponin I | 1 | 2008 | 18 | 0.300 |
Why?
| Sarcoplasmic Reticulum | 4 | 2010 | 21 | 0.300 |
Why?
| Drug Design | 1 | 2008 | 120 | 0.290 |
Why?
| Male | 32 | 2019 | 25093 | 0.290 |
Why?
| Subarachnoid Hemorrhage | 1 | 2008 | 65 | 0.290 |
Why?
| Time Factors | 9 | 2019 | 2912 | 0.280 |
Why?
| Muscle Proteins | 5 | 2007 | 303 | 0.260 |
Why?
| RNA Splice Sites | 1 | 2005 | 10 | 0.250 |
Why?
| Arteriosclerosis | 1 | 2004 | 54 | 0.240 |
Why?
| Testosterone | 6 | 2005 | 139 | 0.240 |
Why?
| Alternative Splicing | 1 | 2005 | 57 | 0.240 |
Why?
| Stents | 3 | 2013 | 338 | 0.240 |
Why?
| Receptors, Adrenergic | 2 | 2001 | 14 | 0.240 |
Why?
| Predictive Value of Tests | 3 | 2013 | 904 | 0.240 |
Why?
| Ventricular Function | 7 | 2005 | 18 | 0.240 |
Why?
| Mutation | 2 | 2008 | 1293 | 0.240 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2005 | 129 | 0.230 |
Why?
| United States | 7 | 2018 | 4838 | 0.230 |
Why?
| Myocardial Ischemia | 2 | 2006 | 120 | 0.230 |
Why?
| Adrenergic beta-Agonists | 6 | 2001 | 40 | 0.230 |
Why?
| Receptors, Androgen | 3 | 2005 | 46 | 0.220 |
Why?
| Gene Expression Regulation | 6 | 2006 | 979 | 0.220 |
Why?
| Muscle Cells | 1 | 2003 | 22 | 0.220 |
Why?
| Treatment Outcome | 5 | 2019 | 5138 | 0.220 |
Why?
| Immunoglobulin Fab Fragments | 1 | 2002 | 16 | 0.220 |
Why?
| Muscle Fibers, Skeletal | 2 | 2001 | 62 | 0.210 |
Why?
| Apoptosis | 2 | 2005 | 1100 | 0.210 |
Why?
| Glucose | 1 | 2005 | 340 | 0.210 |
Why?
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2002 | 32 | 0.210 |
Why?
| Risk Factors | 6 | 2020 | 3619 | 0.210 |
Why?
| Muscle Contraction | 1 | 2003 | 103 | 0.210 |
Why?
| Cell Membrane | 4 | 2017 | 248 | 0.210 |
Why?
| Female | 19 | 2019 | 26329 | 0.200 |
Why?
| Peptides | 1 | 2002 | 222 | 0.200 |
Why?
| Kinetics | 10 | 2010 | 626 | 0.200 |
Why?
| Vasoconstrictor Agents | 1 | 2002 | 84 | 0.190 |
Why?
| Drug Therapy, Combination | 2 | 2013 | 378 | 0.190 |
Why?
| Mibefradil | 1 | 2000 | 1 | 0.190 |
Why?
| Estrogens, Non-Steroidal | 1 | 2000 | 16 | 0.180 |
Why?
| Plants | 1 | 2000 | 27 | 0.180 |
Why?
| 5' Untranslated Regions | 1 | 2000 | 31 | 0.180 |
Why?
| Middle Aged | 11 | 2019 | 11997 | 0.170 |
Why?
| Maximum Tolerated Dose | 1 | 2019 | 37 | 0.170 |
Why?
| Adrenergic alpha-Agonists | 4 | 2001 | 20 | 0.170 |
Why?
| Phenylephrine | 4 | 2001 | 34 | 0.170 |
Why?
| Isoflavones | 1 | 2000 | 89 | 0.170 |
Why?
| Sulfonamides | 1 | 2000 | 129 | 0.170 |
Why?
| Orchiectomy | 3 | 2004 | 41 | 0.170 |
Why?
| Sex Factors | 2 | 2013 | 693 | 0.170 |
Why?
| Administration, Intravenous | 1 | 2019 | 68 | 0.170 |
Why?
| Angiotensin II | 3 | 1999 | 157 | 0.170 |
Why?
| Multivariate Analysis | 2 | 2013 | 585 | 0.170 |
Why?
| Disability Evaluation | 1 | 2019 | 87 | 0.170 |
Why?
| 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester | 6 | 1993 | 9 | 0.170 |
Why?
| Nitric Oxide Donors | 1 | 1998 | 10 | 0.160 |
Why?
| Knee Prosthesis | 1 | 2019 | 49 | 0.160 |
Why?
| Antibodies, Monoclonal | 1 | 2002 | 458 | 0.160 |
Why?
| Drug Administration Schedule | 1 | 2019 | 376 | 0.160 |
Why?
| Recovery of Function | 1 | 2019 | 189 | 0.160 |
Why?
| Genetic Vectors | 2 | 2009 | 127 | 0.160 |
Why?
| Health Care Costs | 1 | 2019 | 170 | 0.150 |
Why?
| Logistic Models | 2 | 2013 | 891 | 0.150 |
Why?
| Animals, Newborn | 7 | 2007 | 366 | 0.150 |
Why?
| Base Sequence | 4 | 2005 | 650 | 0.150 |
Why?
| Risk Assessment | 2 | 2013 | 1262 | 0.150 |
Why?
| Women | 1 | 2017 | 30 | 0.150 |
Why?
| Double-Blind Method | 1 | 2019 | 674 | 0.150 |
Why?
| Schools, Medical | 1 | 2017 | 69 | 0.150 |
Why?
| Mitochondria, Heart | 4 | 2005 | 35 | 0.150 |
Why?
| Blotting, Northern | 3 | 2002 | 109 | 0.140 |
Why?
| Platelet Activation | 1 | 2017 | 46 | 0.140 |
Why?
| Signal Transduction | 3 | 2017 | 1617 | 0.140 |
Why?
| Epinephrine | 1 | 2017 | 96 | 0.140 |
Why?
| Nitric Oxide | 1 | 1998 | 253 | 0.140 |
Why?
| Minority Groups | 1 | 2017 | 132 | 0.140 |
Why?
| Endothelium, Vascular | 3 | 2004 | 254 | 0.140 |
Why?
| Delivery of Health Care | 1 | 2019 | 307 | 0.140 |
Why?
| Receptors, Cholinergic | 1 | 1996 | 14 | 0.140 |
Why?
| Serotonin | 1 | 2017 | 151 | 0.140 |
Why?
| Down-Regulation | 2 | 2008 | 349 | 0.130 |
Why?
| Algorithms | 3 | 2013 | 616 | 0.130 |
Why?
| Catecholamines | 3 | 1996 | 46 | 0.130 |
Why?
| Myocardial Infarction | 1 | 1999 | 382 | 0.130 |
Why?
| Education, Medical, Graduate | 1 | 2018 | 208 | 0.130 |
Why?
| Cardiotonic Agents | 2 | 2010 | 66 | 0.130 |
Why?
| Benzofurans | 2 | 1992 | 17 | 0.130 |
Why?
| Gene Expression Regulation, Developmental | 1 | 1996 | 138 | 0.130 |
Why?
| Myocytes, Smooth Muscle | 2 | 2008 | 87 | 0.130 |
Why?
| Thrombolytic Therapy | 2 | 2010 | 111 | 0.120 |
Why?
| Ribonucleosides | 1 | 1994 | 2 | 0.120 |
Why?
| Aminoimidazole Carboxamide | 1 | 1994 | 3 | 0.120 |
Why?
| Arthroplasty, Replacement, Knee | 1 | 2019 | 278 | 0.120 |
Why?
| Protein Isoforms | 3 | 2007 | 119 | 0.120 |
Why?
| Bradykinin | 3 | 1999 | 17 | 0.120 |
Why?
| Age Factors | 2 | 2013 | 1090 | 0.120 |
Why?
| DNA, Complementary | 2 | 2008 | 135 | 0.120 |
Why?
| Physicians | 1 | 2018 | 234 | 0.120 |
Why?
| Binding Sites | 6 | 2002 | 377 | 0.120 |
Why?
| Myocardial Reperfusion Injury | 1 | 1994 | 48 | 0.120 |
Why?
| Gene Expression | 5 | 2003 | 608 | 0.120 |
Why?
| Heart Rate | 4 | 2001 | 292 | 0.120 |
Why?
| Sodium | 4 | 1992 | 92 | 0.110 |
Why?
| Receptors, Adrenergic, beta-1 | 2 | 2004 | 7 | 0.110 |
Why?
| Cyclic AMP | 5 | 2000 | 90 | 0.110 |
Why?
| Receptors, Purinergic P2Y12 | 1 | 2013 | 12 | 0.110 |
Why?
| Arkansas | 1 | 2019 | 1967 | 0.110 |
Why?
| Dihydropyridines | 3 | 1993 | 8 | 0.110 |
Why?
| Blood Pressure | 3 | 2006 | 514 | 0.110 |
Why?
| Smoking | 1 | 2017 | 510 | 0.110 |
Why?
| NAD | 2 | 2002 | 43 | 0.110 |
Why?
| Therapy, Computer-Assisted | 1 | 2013 | 30 | 0.110 |
Why?
| Drug Resistance | 1 | 2013 | 63 | 0.110 |
Why?
| Educational Measurement | 1 | 2014 | 210 | 0.110 |
Why?
| Calsequestrin | 3 | 2007 | 3 | 0.110 |
Why?
| Ethers, Cyclic | 1 | 1992 | 4 | 0.110 |
Why?
| Tachycardia, Ventricular | 1 | 2013 | 43 | 0.110 |
Why?
| Cell Line | 2 | 2008 | 1002 | 0.110 |
Why?
| Tachycardia, Supraventricular | 1 | 2013 | 40 | 0.110 |
Why?
| Beriberi | 1 | 2012 | 7 | 0.110 |
Why?
| Aged | 6 | 2019 | 9272 | 0.110 |
Why?
| Ganglia, Sympathetic | 1 | 1992 | 3 | 0.100 |
Why?
| Defibrillators, Implantable | 1 | 2013 | 58 | 0.100 |
Why?
| Phosphodiesterase Inhibitors | 2 | 1988 | 23 | 0.100 |
Why?
| Cell Communication | 1 | 1992 | 69 | 0.100 |
Why?
| Prospective Studies | 2 | 2019 | 2344 | 0.100 |
Why?
| Drug Monitoring | 1 | 2012 | 77 | 0.100 |
Why?
| Lipoproteins, LDL | 3 | 2004 | 170 | 0.100 |
Why?
| Protein Kinase C | 2 | 2002 | 71 | 0.100 |
Why?
| Decision Support Techniques | 1 | 2012 | 70 | 0.100 |
Why?
| Odds Ratio | 1 | 2013 | 548 | 0.100 |
Why?
| Immunoblotting | 2 | 2002 | 118 | 0.100 |
Why?
| Electrocardiography | 1 | 2013 | 253 | 0.100 |
Why?
| Oxadiazoles | 2 | 1989 | 10 | 0.090 |
Why?
| Incidence | 2 | 2008 | 1003 | 0.090 |
Why?
| Molecular Sequence Data | 3 | 2002 | 797 | 0.090 |
Why?
| International Normalized Ratio | 1 | 2010 | 29 | 0.090 |
Why?
| Diabetic Angiopathies | 1 | 2010 | 18 | 0.090 |
Why?
| Cyclic AMP-Dependent Protein Kinases | 2 | 2001 | 51 | 0.090 |
Why?
| Cholesterol, LDL | 1 | 2010 | 34 | 0.090 |
Why?
| Evidence-Based Medicine | 1 | 2012 | 248 | 0.090 |
Why?
| Cardiomyopathies | 3 | 2002 | 108 | 0.090 |
Why?
| Foramen Ovale, Patent | 1 | 2010 | 27 | 0.090 |
Why?
| Intracranial Hemorrhages | 1 | 2010 | 39 | 0.090 |
Why?
| Endarterectomy, Carotid | 1 | 2010 | 62 | 0.090 |
Why?
| Adenoviridae | 3 | 2007 | 51 | 0.090 |
Why?
| Thrombectomy | 1 | 2010 | 66 | 0.090 |
Why?
| Action Potentials | 1 | 2010 | 133 | 0.090 |
Why?
| 8-Bromo Cyclic Adenosine Monophosphate | 2 | 2000 | 3 | 0.090 |
Why?
| Gene Transfer Techniques | 1 | 2009 | 37 | 0.090 |
Why?
| Gene Targeting | 1 | 2009 | 30 | 0.090 |
Why?
| Warfarin | 1 | 2010 | 86 | 0.090 |
Why?
| Drug Prescriptions | 1 | 2010 | 95 | 0.080 |
Why?
| Prognosis | 2 | 2008 | 1952 | 0.080 |
Why?
| Percutaneous Coronary Intervention | 1 | 2013 | 299 | 0.080 |
Why?
| Rats, Inbred WKY | 1 | 2008 | 27 | 0.080 |
Why?
| Protein Engineering | 1 | 2008 | 18 | 0.080 |
Why?
| Protein Modification, Translational | 1 | 2007 | 3 | 0.080 |
Why?
| Rats, Inbred SHR | 1 | 2008 | 35 | 0.080 |
Why?
| Atrial Fibrillation | 1 | 2010 | 177 | 0.080 |
Why?
| Nifedipine | 4 | 1990 | 25 | 0.080 |
Why?
| Heart Diseases | 1 | 2010 | 208 | 0.080 |
Why?
| Spectrometry, Fluorescence | 2 | 2002 | 45 | 0.080 |
Why?
| Glasgow Coma Scale | 1 | 2008 | 47 | 0.080 |
Why?
| Acidosis | 1 | 1988 | 40 | 0.080 |
Why?
| Cerebrovascular Disorders | 1 | 2008 | 54 | 0.080 |
Why?
| Mesenteric Arteries | 1 | 2008 | 45 | 0.080 |
Why?
| Medical Records | 1 | 2008 | 83 | 0.080 |
Why?
| Secondary Prevention | 1 | 2008 | 78 | 0.080 |
Why?
| Anticoagulants | 1 | 2010 | 254 | 0.070 |
Why?
| Triiodothyronine | 1 | 1987 | 29 | 0.070 |
Why?
| Homeostasis | 4 | 2002 | 199 | 0.070 |
Why?
| Thrombosis | 1 | 2010 | 249 | 0.070 |
Why?
| Cholesterol | 1 | 2008 | 146 | 0.070 |
Why?
| Cell Culture Techniques | 2 | 2005 | 99 | 0.070 |
Why?
| Dogs | 3 | 2007 | 182 | 0.070 |
Why?
| Diabetes Mellitus, Type 2 | 1 | 2013 | 467 | 0.070 |
Why?
| Recombinant Fusion Proteins | 1 | 2008 | 182 | 0.070 |
Why?
| Cerebral Hemorrhage | 1 | 2008 | 104 | 0.070 |
Why?
| Propranolol | 3 | 1994 | 78 | 0.070 |
Why?
| Adrenergic beta-Antagonists | 3 | 2017 | 102 | 0.070 |
Why?
| Proteasome Endopeptidase Complex | 1 | 2007 | 114 | 0.070 |
Why?
| Pyridones | 1 | 1987 | 34 | 0.070 |
Why?
| Aorta | 2 | 2005 | 160 | 0.070 |
Why?
| Adult | 9 | 2017 | 13160 | 0.070 |
Why?
| 1-Methyl-3-isobutylxanthine | 4 | 1998 | 8 | 0.070 |
Why?
| Verapamil | 5 | 1994 | 22 | 0.070 |
Why?
| Angina Pectoris | 1 | 1986 | 18 | 0.070 |
Why?
| Drug Delivery Systems | 1 | 2008 | 136 | 0.070 |
Why?
| Vasodilator Agents | 1 | 1987 | 97 | 0.070 |
Why?
| Arteriovenous Fistula | 1 | 1986 | 21 | 0.070 |
Why?
| Aortic Aneurysm | 1 | 1986 | 25 | 0.070 |
Why?
| Carrier Proteins | 1 | 2007 | 304 | 0.070 |
Why?
| Carotid Stenosis | 1 | 2006 | 63 | 0.070 |
Why?
| Vena Cava, Inferior | 1 | 1986 | 79 | 0.070 |
Why?
| Hospital Mortality | 1 | 2008 | 413 | 0.060 |
Why?
| Aortic Diseases | 1 | 1986 | 54 | 0.060 |
Why?
| Cytoskeleton | 1 | 1985 | 39 | 0.060 |
Why?
| Culture Media, Serum-Free | 1 | 2005 | 15 | 0.060 |
Why?
| Cytoskeletal Proteins | 1 | 1985 | 49 | 0.060 |
Why?
| Mannitol | 1 | 2005 | 14 | 0.060 |
Why?
| Alprenolol | 1 | 1985 | 1 | 0.060 |
Why?
| Inhibitor of Apoptosis Proteins | 1 | 2005 | 20 | 0.060 |
Why?
| Restriction Mapping | 1 | 2005 | 33 | 0.060 |
Why?
| Tumor Necrosis Factors | 1 | 2004 | 8 | 0.060 |
Why?
| In Situ Nick-End Labeling | 1 | 2005 | 57 | 0.060 |
Why?
| Casein Kinase II | 1 | 2004 | 10 | 0.060 |
Why?
| Muscle, Smooth | 1 | 2004 | 63 | 0.060 |
Why?
| DNA Primers | 1 | 2005 | 206 | 0.060 |
Why?
| bcl-X Protein | 1 | 2005 | 50 | 0.060 |
Why?
| Cloning, Molecular | 1 | 2005 | 189 | 0.060 |
Why?
| Tissue Distribution | 1 | 2005 | 164 | 0.060 |
Why?
| Myosin Heavy Chains | 1 | 2004 | 20 | 0.060 |
Why?
| Coronary Artery Bypass | 2 | 2010 | 120 | 0.060 |
Why?
| Ligands | 1 | 2004 | 204 | 0.060 |
Why?
| Protein Structure, Tertiary | 1 | 2005 | 253 | 0.060 |
Why?
| Antihypertensive Agents | 2 | 2020 | 115 | 0.060 |
Why?
| Calcium-Calmodulin-Dependent Protein Kinases | 2 | 2005 | 34 | 0.060 |
Why?
| Pyridines | 1 | 1985 | 130 | 0.060 |
Why?
| Calcium Radioisotopes | 3 | 1989 | 7 | 0.060 |
Why?
| Temperature | 1 | 2004 | 168 | 0.060 |
Why?
| Gonadal Steroid Hormones | 2 | 2003 | 42 | 0.060 |
Why?
| Androgens | 1 | 2004 | 69 | 0.060 |
Why?
| Osmolar Concentration | 3 | 1992 | 62 | 0.060 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 595 | 0.060 |
Why?
| Angiography | 1 | 1983 | 126 | 0.060 |
Why?
| Diagnosis, Differential | 2 | 2013 | 1036 | 0.050 |
Why?
| DNA Footprinting | 1 | 2002 | 9 | 0.050 |
Why?
| Ion Channel Gating | 2 | 2006 | 39 | 0.050 |
Why?
| Proto-Oncogene Proteins c-ets | 1 | 2002 | 8 | 0.050 |
Why?
| Luminescent Proteins | 1 | 2003 | 53 | 0.050 |
Why?
| Green Fluorescent Proteins | 1 | 2003 | 90 | 0.050 |
Why?
| Regulatory Sequences, Nucleic Acid | 1 | 2002 | 41 | 0.050 |
Why?
| Electrophoretic Mobility Shift Assay | 1 | 2002 | 73 | 0.050 |
Why?
| Coculture Techniques | 2 | 2003 | 146 | 0.050 |
Why?
| Pulmonary Embolism | 1 | 1983 | 97 | 0.050 |
Why?
| Vasodilation | 1 | 2003 | 97 | 0.050 |
Why?
| Cardiac Pacing, Artificial | 2 | 1994 | 28 | 0.050 |
Why?
| Macrophages | 1 | 2004 | 364 | 0.050 |
Why?
| Proteins | 1 | 2005 | 341 | 0.050 |
Why?
| Proto-Oncogene Proteins | 1 | 2002 | 149 | 0.050 |
Why?
| Receptors, Nicotinic | 2 | 1992 | 76 | 0.050 |
Why?
| Lovastatin | 2 | 1993 | 9 | 0.050 |
Why?
| Chronic Disease | 2 | 2003 | 563 | 0.050 |
Why?
| Acute Disease | 1 | 2002 | 369 | 0.050 |
Why?
| Systole | 2 | 1990 | 68 | 0.050 |
Why?
| Blotting, Western | 1 | 2003 | 602 | 0.050 |
Why?
| Phenylalanine | 2 | 1999 | 128 | 0.050 |
Why?
| Polymerase Chain Reaction | 2 | 2002 | 455 | 0.050 |
Why?
| Electrophysiology | 3 | 1996 | 78 | 0.050 |
Why?
| Pulmonary Artery | 1 | 2002 | 145 | 0.050 |
Why?
| Chronotherapy | 1 | 2020 | 2 | 0.050 |
Why?
| Enzyme Inhibitors | 2 | 2000 | 391 | 0.050 |
Why?
| Hemorrhage | 1 | 2002 | 202 | 0.050 |
Why?
| Nuclear Proteins | 1 | 2002 | 243 | 0.050 |
Why?
| Isoquinolines | 1 | 2000 | 25 | 0.050 |
Why?
| Isradipine | 3 | 1993 | 5 | 0.050 |
Why?
| Biological Transport | 1 | 2001 | 173 | 0.050 |
Why?
| Culture Media | 3 | 1993 | 93 | 0.050 |
Why?
| Inflammation | 1 | 2004 | 604 | 0.050 |
Why?
| Electrophoresis | 1 | 2000 | 16 | 0.050 |
Why?
| Phytoestrogens | 1 | 2000 | 22 | 0.050 |
Why?
| RNA, Antisense | 1 | 2000 | 6 | 0.040 |
Why?
| Genetic Complementation Test | 1 | 2000 | 48 | 0.040 |
Why?
| Luciferases | 1 | 2000 | 50 | 0.040 |
Why?
| Plant Preparations | 1 | 2000 | 37 | 0.040 |
Why?
| Up-Regulation | 3 | 2017 | 450 | 0.040 |
Why?
| Clinical Trials as Topic | 1 | 2002 | 460 | 0.040 |
Why?
| Drug Interactions | 1 | 2000 | 206 | 0.040 |
Why?
| Genes, Reporter | 1 | 2000 | 89 | 0.040 |
Why?
| Electrophoresis, Polyacrylamide Gel | 1 | 2000 | 103 | 0.040 |
Why?
| Lung | 1 | 1983 | 480 | 0.040 |
Why?
| Stimulation, Chemical | 3 | 1990 | 28 | 0.040 |
Why?
| Decision Trees | 1 | 1999 | 19 | 0.040 |
Why?
| Cell Nucleus | 1 | 2000 | 184 | 0.040 |
Why?
| Ribosomal Protein S6 Kinases | 1 | 1999 | 8 | 0.040 |
Why?
| Stress, Mechanical | 1 | 1979 | 88 | 0.040 |
Why?
| Transfection | 1 | 2000 | 357 | 0.040 |
Why?
| Canada | 1 | 2019 | 98 | 0.040 |
Why?
| omega-N-Methylarginine | 1 | 1998 | 3 | 0.040 |
Why?
| Iloprost | 1 | 1998 | 4 | 0.040 |
Why?
| Sodium-Potassium-Exchanging ATPase | 2 | 1993 | 61 | 0.040 |
Why?
| Molsidomine | 1 | 1998 | 5 | 0.040 |
Why?
| Nitroprusside | 1 | 1998 | 10 | 0.040 |
Why?
| Cyclic GMP | 1 | 1998 | 20 | 0.040 |
Why?
| Transcription Factors | 1 | 2002 | 563 | 0.040 |
Why?
| Indomethacin | 1 | 1998 | 38 | 0.040 |
Why?
| Prosthesis Failure | 1 | 2019 | 107 | 0.040 |
Why?
| Consensus Development Conferences as Topic | 1 | 2018 | 12 | 0.040 |
Why?
| Osteoarthritis, Knee | 1 | 2019 | 88 | 0.040 |
Why?
| Hypertrophy, Left Ventricular | 1 | 1998 | 34 | 0.040 |
Why?
| Prosthesis Design | 1 | 2019 | 236 | 0.040 |
Why?
| Research Support as Topic | 1 | 2018 | 46 | 0.040 |
Why?
| Propanolamines | 2 | 1988 | 14 | 0.040 |
Why?
| Serotonin 5-HT2 Receptor Antagonists | 1 | 2017 | 9 | 0.040 |
Why?
| Transglutaminases | 1 | 2017 | 15 | 0.040 |
Why?
| Patch-Clamp Techniques | 1 | 1997 | 124 | 0.040 |
Why?
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2017 | 63 | 0.040 |
Why?
| Heart Failure | 2 | 1993 | 454 | 0.040 |
Why?
| Polysaccharides | 1 | 2017 | 50 | 0.040 |
Why?
| Platelet Aggregation | 1 | 2017 | 71 | 0.040 |
Why?
| Cell Division | 3 | 2003 | 292 | 0.040 |
Why?
| Protein Transport | 1 | 2017 | 179 | 0.030 |
Why?
| Cell Movement | 2 | 2003 | 247 | 0.030 |
Why?
| Protein Biosynthesis | 1 | 1998 | 253 | 0.030 |
Why?
| Enkephalins | 2 | 1986 | 6 | 0.030 |
Why?
| Glycosylation | 2 | 2007 | 100 | 0.030 |
Why?
| Chromatography, High Pressure Liquid | 1 | 2017 | 349 | 0.030 |
Why?
| Tandem Mass Spectrometry | 1 | 2017 | 236 | 0.030 |
Why?
| Pindolol | 2 | 1985 | 4 | 0.030 |
Why?
| Calibration | 2 | 1992 | 58 | 0.030 |
Why?
| GTP-Binding Proteins | 2 | 1993 | 90 | 0.030 |
Why?
| Fluorescent Dyes | 2 | 1992 | 101 | 0.030 |
Why?
| Extracellular Space | 2 | 1993 | 38 | 0.030 |
Why?
| Purinergic P1 Receptor Antagonists | 1 | 1994 | 2 | 0.030 |
Why?
| Theophylline | 1 | 1994 | 19 | 0.030 |
Why?
| Curriculum | 1 | 2018 | 404 | 0.030 |
Why?
| Case-Control Studies | 1 | 2017 | 1128 | 0.030 |
Why?
| Transforming Growth Factor beta | 1 | 1994 | 144 | 0.030 |
Why?
| Caspases | 2 | 2005 | 104 | 0.030 |
Why?
| Phosphorylation | 2 | 2005 | 536 | 0.030 |
Why?
| Cell Separation | 3 | 2005 | 88 | 0.030 |
Why?
| Cardiomyopathy, Dilated | 1 | 1993 | 36 | 0.030 |
Why?
| Dose-Response Relationship, Drug | 2 | 1988 | 1374 | 0.030 |
Why?
| Receptors, Drug | 1 | 1993 | 4 | 0.030 |
Why?
| Digoxin | 1 | 1993 | 21 | 0.030 |
Why?
| Diagnosis, Computer-Assisted | 1 | 2013 | 48 | 0.030 |
Why?
| Cytological Techniques | 1 | 1992 | 14 | 0.030 |
Why?
| Magnesium | 1 | 1992 | 35 | 0.030 |
Why?
| Disease Models, Animal | 2 | 1994 | 1451 | 0.030 |
Why?
| Internship and Residency | 1 | 2018 | 446 | 0.030 |
Why?
| Ouabain | 3 | 1993 | 28 | 0.030 |
Why?
| Urinary Tract Infections | 1 | 2012 | 52 | 0.030 |
Why?
| Potassium | 3 | 1993 | 57 | 0.020 |
Why?
| Adenine Nucleotides | 1 | 1991 | 4 | 0.020 |
Why?
| Cyanides | 1 | 1991 | 5 | 0.020 |
Why?
| Potassium Chloride | 1 | 1991 | 20 | 0.020 |
Why?
| Electron Transport | 1 | 1991 | 25 | 0.020 |
Why?
| Lactates | 1 | 1991 | 29 | 0.020 |
Why?
| Cricetinae | 3 | 2002 | 192 | 0.020 |
Why?
| Deoxyglucose | 1 | 1991 | 36 | 0.020 |
Why?
| Rats, Inbred Strains | 1 | 1991 | 196 | 0.020 |
Why?
| Aorta, Abdominal | 2 | 1994 | 41 | 0.020 |
Why?
| Malnutrition | 1 | 2012 | 87 | 0.020 |
Why?
| Fluoresceins | 1 | 1990 | 11 | 0.020 |
Why?
| Sensitivity and Specificity | 1 | 2013 | 854 | 0.020 |
Why?
| Oxidation-Reduction | 1 | 1991 | 319 | 0.020 |
Why?
| Adenosine Triphosphate | 1 | 1991 | 234 | 0.020 |
Why?
| Thyroid Hormones | 1 | 1990 | 18 | 0.020 |
Why?
| Cardiac Catheterization | 2 | 1983 | 196 | 0.020 |
Why?
| Infant | 1 | 1998 | 3551 | 0.020 |
Why?
| Phenethylamines | 1 | 1989 | 8 | 0.020 |
Why?
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2010 | 66 | 0.020 |
Why?
| Hospitals, Veterans | 1 | 2010 | 110 | 0.020 |
Why?
| Tritium | 2 | 1993 | 47 | 0.020 |
Why?
| Tetrodotoxin | 1 | 1989 | 10 | 0.020 |
Why?
| Reproducibility of Results | 1 | 2013 | 1188 | 0.020 |
Why?
| Sodium Channels | 1 | 1989 | 14 | 0.020 |
Why?
| Depression, Chemical | 1 | 1988 | 13 | 0.020 |
Why?
| Energy Metabolism | 1 | 1991 | 281 | 0.020 |
Why?
| Bupivacaine | 1 | 1989 | 28 | 0.020 |
Why?
| Lidocaine | 1 | 1989 | 49 | 0.020 |
Why?
| Heart Transplantation | 1 | 1993 | 312 | 0.020 |
Why?
| Aspirin | 1 | 2010 | 114 | 0.020 |
Why?
| Amiloride | 1 | 1988 | 8 | 0.020 |
Why?
| Aerobiosis | 1 | 1988 | 13 | 0.020 |
Why?
| Anaerobiosis | 1 | 1988 | 16 | 0.020 |
Why?
| Free Radicals | 1 | 1988 | 28 | 0.020 |
Why?
| Oxygen | 2 | 1982 | 325 | 0.020 |
Why?
| Catalase | 1 | 1988 | 67 | 0.020 |
Why?
| Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase | 1 | 2007 | 1 | 0.020 |
Why?
| Leupeptins | 1 | 2007 | 7 | 0.020 |
Why?
| Tunicamycin | 1 | 2007 | 11 | 0.020 |
Why?
| Cysteine Proteinase Inhibitors | 1 | 2007 | 22 | 0.020 |
Why?
| Ryanodine Receptor Calcium Release Channel | 1 | 2007 | 13 | 0.020 |
Why?
| Superoxide Dismutase | 1 | 1988 | 113 | 0.020 |
Why?
| COS Cells | 1 | 2007 | 75 | 0.020 |
Why?
| Cell Membrane Permeability | 2 | 1987 | 28 | 0.020 |
Why?
| Hydrogen-Ion Concentration | 1 | 1988 | 174 | 0.020 |
Why?
| Sarcolemma | 1 | 1987 | 2 | 0.020 |
Why?
| Socioeconomic Factors | 1 | 2010 | 580 | 0.020 |
Why?
| Radioligand Assay | 1 | 1987 | 46 | 0.020 |
Why?
| Milrinone | 1 | 1987 | 9 | 0.020 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2007 | 142 | 0.020 |
Why?
| Binding, Competitive | 1 | 1987 | 95 | 0.020 |
Why?
| Proteasome Inhibitors | 1 | 2007 | 104 | 0.020 |
Why?
| Pulmonary Circulation | 2 | 1983 | 34 | 0.020 |
Why?
| Phenotype | 2 | 2003 | 727 | 0.020 |
Why?
| Caspase 8 | 1 | 2005 | 12 | 0.020 |
Why?
| Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2005 | 13 | 0.020 |
Why?
| Cats | 1 | 2005 | 79 | 0.020 |
Why?
| Membrane Potentials | 1 | 2006 | 117 | 0.020 |
Why?
| Chi-Square Distribution | 1 | 2006 | 282 | 0.020 |
Why?
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2005 | 17 | 0.020 |
Why?
| bcl-2-Associated X Protein | 1 | 2005 | 56 | 0.020 |
Why?
| Protein Conformation | 1 | 2006 | 166 | 0.020 |
Why?
| Heart Neoplasms | 1 | 1985 | 33 | 0.020 |
Why?
| Testosterone Propionate | 1 | 2005 | 2 | 0.020 |
Why?
| Guanylyl Imidodiphosphate | 1 | 1985 | 1 | 0.020 |
Why?
| Phosphoprotein Phosphatases | 1 | 2004 | 17 | 0.020 |
Why?
| Phosphates | 1 | 2004 | 47 | 0.020 |
Why?
| Carcinoma | 1 | 1985 | 137 | 0.010 |
Why?
| Thyroid Neoplasms | 1 | 1985 | 109 | 0.010 |
Why?
| Ventilation-Perfusion Ratio | 1 | 1983 | 6 | 0.010 |
Why?
| Echocardiography | 2 | 1993 | 378 | 0.010 |
Why?
| Nitrendipine | 1 | 1983 | 1 | 0.010 |
Why?
| Diltiazem | 1 | 1983 | 10 | 0.010 |
Why?
| Evaluation Studies as Topic | 1 | 1983 | 106 | 0.010 |
Why?
| Radionuclide Imaging | 1 | 1983 | 116 | 0.010 |
Why?
| Ion Exchange | 1 | 2002 | 1 | 0.010 |
Why?
| Pressure | 1 | 2003 | 102 | 0.010 |
Why?
| Risk | 1 | 1983 | 320 | 0.010 |
Why?
| Sex Characteristics | 1 | 2004 | 190 | 0.010 |
Why?
| Hemodynamics | 1 | 1983 | 229 | 0.010 |
Why?
| Organ Size | 1 | 2002 | 226 | 0.010 |
Why?
| Enzyme Activation | 1 | 2002 | 276 | 0.010 |
Why?
| Anti-Bacterial Agents | 1 | 2007 | 743 | 0.010 |
Why?
| Heart Atria | 2 | 1993 | 55 | 0.010 |
Why?
| Retrospective Studies | 1 | 2013 | 6117 | 0.010 |
Why?
| Dihydroalprenolol | 1 | 1980 | 3 | 0.010 |
Why?
| Pulse | 1 | 1979 | 14 | 0.010 |
Why?
| Oximetry | 1 | 1980 | 66 | 0.010 |
Why?
| Models, Biological | 1 | 2003 | 728 | 0.010 |
Why?
| Carotid Arteries | 1 | 1979 | 85 | 0.010 |
Why?
| Flavonoids | 1 | 1999 | 58 | 0.010 |
Why?
| Sirolimus | 1 | 1999 | 62 | 0.010 |
Why?
| Endothelium | 1 | 1998 | 39 | 0.010 |
Why?
| Postoperative Complications | 1 | 1983 | 1000 | 0.010 |
Why?
| Naloxone | 2 | 1986 | 77 | 0.010 |
Why?
| Prazosin | 1 | 1994 | 10 | 0.010 |
Why?
| Atrial Natriuretic Factor | 1 | 1994 | 21 | 0.010 |
Why?
| Culture Media, Conditioned | 1 | 1994 | 48 | 0.010 |
Why?
| Constriction, Pathologic | 1 | 1994 | 94 | 0.010 |
Why?
| Turkeys | 1 | 1993 | 11 | 0.010 |
Why?
| Computers | 1 | 1994 | 47 | 0.010 |
Why?
| Virulence Factors, Bordetella | 1 | 1993 | 8 | 0.010 |
Why?
| Pertussis Toxin | 1 | 1993 | 11 | 0.010 |
Why?
| Neoplasms | 1 | 1983 | 1233 | 0.010 |
Why?
| Fetal Blood | 1 | 1993 | 67 | 0.010 |
Why?
| Cattle | 1 | 1993 | 210 | 0.010 |
Why?
| Calcium-Transporting ATPases | 1 | 1992 | 14 | 0.010 |
Why?
| Fibroblasts | 1 | 1994 | 343 | 0.010 |
Why?
| Ventricular Function, Left | 1 | 1993 | 154 | 0.010 |
Why?
| Analysis of Variance | 1 | 1993 | 565 | 0.010 |
Why?
| Stroke Volume | 1 | 1993 | 115 | 0.010 |
Why?
| Cell Survival | 1 | 1993 | 598 | 0.010 |
Why?
| Amino Acid Sequence | 1 | 1992 | 587 | 0.010 |
Why?
| Mesocricetus | 1 | 1990 | 6 | 0.010 |
Why?
| Fura-2 | 1 | 1990 | 2 | 0.010 |
Why?
| Lanthanum | 1 | 1990 | 4 | 0.010 |
Why?
| Diastole | 1 | 1990 | 69 | 0.010 |
Why?
| Fluorescence | 1 | 1990 | 41 | 0.010 |
Why?
| Reference Values | 1 | 1990 | 310 | 0.010 |
Why?
| Adenosine Diphosphate Ribose | 1 | 1989 | 8 | 0.010 |
Why?
| Atrial Function | 1 | 1989 | 6 | 0.010 |
Why?
| Cholera Toxin | 1 | 1989 | 15 | 0.010 |
Why?
| Oxidative Phosphorylation | 1 | 1987 | 39 | 0.000 |
Why?
| Glycolysis | 1 | 1987 | 70 | 0.000 |
Why?
| Enkephalin, Methionine | 1 | 1986 | 3 | 0.000 |
Why?
| Oxygen Consumption | 1 | 1987 | 180 | 0.000 |
Why?
| Pulmonary Valve Stenosis | 1 | 1985 | 13 | 0.000 |
Why?
| Receptors, Opioid | 1 | 1985 | 18 | 0.000 |
Why?
| Aging | 1 | 1990 | 688 | 0.000 |
Why?
| Adolescent | 1 | 1992 | 6340 | 0.000 |
Why?
| Coronary Circulation | 1 | 1980 | 57 | 0.000 |
Why?
| Regional Blood Flow | 1 | 1980 | 108 | 0.000 |
Why?
| Hemoglobins | 1 | 1980 | 108 | 0.000 |
Why?
| Brain | 1 | 1985 | 1309 | 0.000 |
Why?
|
|
Marsh's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|